A Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 13 Aug 2019
Price : $35 *
At a glance
- Drugs Eltrombopag (Primary) ; Antithymocyte globulin; Ciclosporin
- Indications Aplastic anaemia
- Focus Therapeutic Use
- Acronyms RACE
- 08 Aug 2019 Planned End Date changed from 1 Jun 2021 to 1 Jul 2021.
- 08 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 22 Aug 2018 Planned End Date changed from 1 Aug 2018 to 1 Jun 2021.